Rep. Gilbert Cisneros Buys Vaxcyte (PCVX) Stock
Gilbert Cisneros, a member of the House, bought shares of Vaxcyte Inc. valued between $1,001 and $15,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Cisneros bought between $1,001 and $15,000 of Vaxcyte, Inc. ($PCVX) stock on May 13, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed June 9, 2026.
Since the trade, $PCVX is down 13.1% after 1 week, down 12.5% after 1 month and up 17.3% to date (from the $54.25 close on May 13, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Cisneros (D-CA)
- Status:
- Member — House
- State/District:
- CA-31
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Vaxcyte, Inc. ($PCVX) | Buy | May 13, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
PCVX
Vaxcyte, Inc.
Key Points
- On May 13, 2026, Rep. Gilbert Cisneros purchased shares of Vaxcyte Inc. (PCVX) valued between $1,001 and $15,000, with a reported transaction on June 9.
- Vaxcyte's shares closed at $58.13 prior to Cisneros's purchase and currently trade at around $47.46, down significantly from a 52-week high of $65.00.
- Analysts continue to favor Vaxcyte, with a consensus rating of 'strong buy' and a mean price target of $109.00, suggesting potential for significant price appreciation.
Get $PCVX trade alerts by text
We text you when insiders, Congress or big funds trade $PCVX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Vaxcyte, Inc. alert may contain errors. Disclosures
Gilbert Cisneros's Recent Stock Purchase
On May 13, 2026, U.S. House member Gilbert Cisneros bought shares of Vaxcyte Inc. (PCVX) valued between $1,001 and $15,000. This transaction was reported on June 9, 2026. At the time of purchase, the shares were trading at approximately $47.46.
Gilbert Cisneros vs. the S&P 500
Hypothetical returns from Gilbert Cisneros's disclosed trades, not real profit or advice. How we model this.
Context of the Purchase
Cisneros's move adds to his previous investments in the biotech sector, aligning with Vaxcyte's focus on innovative vaccines. His recent buy follows a reported share price of $58.13 prior to this purchase, reflecting a notable drop as the stock currently trades below its 52-week high of $65.00.
Institutional Sentiment
There were no recent institutional transactions reported for Vaxcyte that could provide additional context to Cisneros's investment.
How PCVX Stock Has Traded
Vaxcyte's stock has seen fluctuations, currently priced around $47.46, which is down from its previous close of $58.13. The stock sits well above its 52-week low of $31.89, indicating some resilience, but the decline from the high of $65.00 raises questions for investors about the company's market positioning.
Recent Insider Activity
On June 18, 2026, Grant Pickering, Vaxcyte's CEO, purchased 225 shares at an average price of $1.79, totaling about $402.75. In contrast, CFO Andrew Guggenhime sold 10,000 shares at $53.00 as part of a planned transaction and also bought 10,000 shares at $5.35 in an unplanned sale. This insider activity reflects varying confidence among leadership in the company’s future.
Analysts Set New Price Targets
Analysts remain optimistic about Vaxcyte, with firms like Cantor Fitzgerald reiterating their 'Overweight' rating on October 12, 2026, and maintaining a target price of $120. Other firms such as Needham and Guggenheim have also maintained 'Buy' ratings with price targets ranging from $122 to $125, indicating strong belief in the company's growth potential.
What PCVX Does
Vaxcyte Inc. is a clinical-stage biotechnology company based in San Carlos, California. It focuses on developing innovative vaccines aimed at preventing and treating bacterial infections. This aligns with the interests of Cisneros, whose district may benefit from advancements in healthcare and biotechnology.
What's Ahead for PCVX
As Vaxcyte prepares for its next earnings report on November 3, 2026, investors will be keen to see how the company's performance aligns with analyst expectations. The 13F filings reflect past holdings and may not capture the current sentiment in the market, but insiders' mixed actions may hint at the company's future direction.
Related Filing Alerts
Source: Gilbert Cisneros's STOCK Act disclosure on $PCVX (May 13, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts